Institut Català de la Salut
[Ospina-Serrano AV, Collazo-Lorduy A] Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. [Azkona-Uribelarrea E] Hospital Universitario Cruces, Barakaldo, Spain. [Guillen-Sentís P] Institut Català d’Oncologia—Badalona, Barcelona, Spain. [Aparisi F] Hospital Universitari i Politècnic La Fe, Valencia, Spain. [López R] Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Valdivia A] Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-05-14T06:21:00Z
2025-05-14T06:21:00Z
2025-04
Lung cancer; Oncological treatment; Sexual dysfunction
Cáncer de pulmón; Tratamiento oncológico; Disfunción sexual
Càncer de pulmó; Tractament oncològic; Disfunció sexual
Background Patients with lung cancer may suffer from sexual dysfunction (SD) related to oncological treatment. This is an under-recognized condition among clinicians. The aim of this study was to describe the prevalence of SD in a multicenter cohort of patients. Patients and methods This multicenter, cross-sectional, observational study was conducted between July 2023 and February 2024. Sexual function was assessed by patient-reported outcome (PRO) system using sex-specific questionnaire. Descriptive analysis and evaluation of differences between categorical variables were carried out. Associations between clinical characteristics and SD were assessed by logistic regression. Results Four hundred and forty-eight patients from 24 hospitals in Spain, Colombia, Argentina, and Portugal were included. Of these, 277 (61.83%) were male and 365 (81.48%) had metastatic disease. Two hundred and eighty-four patients (63.39%) reported the onset of SD following the initiation of oncological treatment. Males and females reported a high frequency of severe impairment of sexual response phases, which was twice as high in females (P = 0.001). Female sex was a factor for severe impairment of desire, arousal, and orgasm [odds ratio (OR) 3.72, 95% confidence interval (CI) 2.48-5.60, P = 0.001] and decreased sexual activity (OR 1.98, 95% CI:1.17-3.19, P = 0.01), in addition to age over 65 years (OR 3.86, 95% CI 1.01-15.25, P = 0.004) and high educational level (OR 0.29, 95% CI 0.09-0.94, P = 0.0040). Patients from Portugal and Latin America were more likely to report dissatisfaction with sexual activity (OR 3.75, 95% CI 1.06-13.22, P = 0.0039). Female sex (OR 3.53, 95% CI 1.88-6.6, P 0.001), smoking history (OR 1.77, 95% CI 1.01-4.01, P = 0.04), and obesity (OR 1.70 95% CI 1.01-3.16, P = 0.05) were associated with global sexual dissatisfaction. Conclusions Our patients with lung cancer had a high prevalence of SD after initiation of oncological treatment. There was remarkable sex disparity in the frequency and severity of this disorder as well as an important influence of sociocultural factors in the clinical presentation.
This academic research was developed by the Spanish Lung Cancer Group/Grupo Español de Cancer de Pulmón GECP (no grant number).
Article
Published version
English
Qüestionaris; Pulmons - Càncer; Trastorns sexuals; Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence; DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms; DISEASES::Male Urogenital Diseases::Genital Diseases, Male::Sexual Dysfunction, Physiological; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents; Other subheadings::Other subheadings::Other subheadings::/adverse effects; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::prevalencia; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares; ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades de los genitales masculinos::disfunción sexual fisiológica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
Elsevier
ESMO Open;10(4)
https://doi.org/10.1016/j.esmoop.2025.104539
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]